Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED · Alpha
██.█% Sign up free to reveal

Veradermics, Inc (MANE) AI Forecast

Our AI ranks Veradermics, Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$MANE Bullish Signal Full forecast available
Sign Up Free

Veradermics, Inc (MANE) Stock Forecast Sept. 25, 2026

Veradermics, Inc (MANE) AI Stock Price Forecast & Investment Analysis

Veradermics, Inc Stock Price Chart and Technical Analysis

Loading chart...

Veradermics, Inc (MANE) - Comprehensive Stock Analysis & Investment Research

Deep dive into Veradermics, Inc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on Sept. 25, 2026 (UTC)

Veradermics, Inc Investment Summary

When evaluating whether Veradermics, Inc (MANE) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Veradermics, Inc (MANE) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. With a market capitalization of $5 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Veradermics, Inc's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Veradermics, Inc along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Veradermics, Inc is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Veradermics, Inc

Sign Up Free
Corporate Identity

Veradermics, Inc (Stock Symbol: MANE) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the NYSE exchange.

Leadership & Workforce

Detailed information about Veradermics, Inc's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Veradermics, Inc...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Veradermics, Inc...

Unlock Full Company Profile

Get complete details about Veradermics, Inc

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Veradermics, Inc...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Veradermics, Inc...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Veradermics, Inc...

Unlock Financial Analysis

Get complete financial metrics for Veradermics, Inc

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Veradermics, Inc's AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Veradermics, Inc strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Veradermics, Inc competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency
Financial Strength & Leverage

The current ratio stands at 70.53. This demonstrates strong short-term liquidity, with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Veradermics, Inc (MANE) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Veradermics, Inc stock analysis.

Deep dive into Veradermics, Inc's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Veradermics, Inc stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Veradermics, Inc:

P/B Ratio 5.99x
Market Cap $4.87B
Book Value/Share $19.47
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Veradermics, Inc converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Veradermics, Inc:

Understanding Financial Health Metrics

What these metrics mean: These ratios assess Veradermics, Inc's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Veradermics, Inc: A current ratio of 70.53 indicates strong liquidity.

Current Ratio 70.53x
D/E Ratio 0.01x
Financial Leverage 1.01x
Working Capital $813M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Veradermics, Inc's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Veradermics, Inc:

Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Veradermics, Inc uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Veradermics, Inc:

Understanding Financial Statement Data

What these metrics mean: Key figures from Veradermics, Inc's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Veradermics, Inc:

Income Statement
Balance Sheet Highlights (USD millions)
Total Current Assets $825M (99.9% of assets)
Cash & Short-term Investments $319M (38.7% of assets)
Total Liabilities $12M (1.5% of assets)
Short-term Debt $6M (0.7% of assets)
Dividend & Shareholder Information
Shares Outstanding 42M

Latest Veradermics, Inc Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Veradermics, Inc (MANE) stock price and investment outlook.

📰 Loading...

Where MANE sits on the market map

Explore the map →

Veradermics, Inc Industry Peers - Pharmaceutical Preparations

Companies classified under the same SEC industry code as Veradermics, Inc (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
MANE ██% $4.87B x 6.0x
LLY ██% $1.11T 41.7x 113.4x
JNJ ██% $653.61B 31.1x 7.7x
ONC ██% $533.38B x 103.1x
ABBV ██% $468.50B 74.3x x
MRK ██% $367.07B 115.7x 8.8x
NVS ██% $277.56B x x
GSK ██% $212.49B x x
ABT ██% $176.04B 28.6x 3.5x
PFE ██% $163.41B 37.7x 1.9x
VRTX ██% $132.40B 30.1x 6.5x
BMY ██% $128.41B 13.8x 5.8x
REGN ██% $81.13B 18.7x 2.6x
SNY ██% $49.92B x x
TEVA ██% $46.87B 66.3x 6.1x
ATHE ██% $34.41B x x
ALNY ██% $34.25B x 25.3x
RPRX ██% $33.47B 41.1x 4.9x
TAK ██% $29.58B x x
ZTS ██% $29.04B 11.1x 9.2x
ZLAB ██% $28.38B x 46.7x
ROIV ██% $25.86B x 6.1x
INSM ██% $25.73B x 34.0x
UTHR ██% $20.25B 15.5x 3.2x
VTRS ██% $20.01B x x
JAZZ ██% $15.45B 16.4x 3.2x
ASND ██% $13.98B x x
SMMT ██% $13.07B x 20.7x
BBIO ██% $12.82B x x
CORT ██% $12.55B x 17.8x
HCM ██% $12.16B x 9.8x
MDGL ██% $11.93B x 22.8x
KNSA ██% $11.72B x 19.3x
BMRN ██% $11.66B x 1.9x
ELAN ██% $11.15B x 1.7x
RDY ██% $10.22B x x
AXSM ██% $10.22B x 122.7x
ARWR ██% $9.31B x 20.0x
PTGX ██% $9.18B x 10.9x
CYTK ██% $8.99B x x
PRAX ██% $7.84B x 5.9x
GPCR ██% $7.69B x 5.7x
SYRE ██% $7.68B x 7.0x
ABVX ██% $7.45B x x
IONS ██% $7.40B x 16.8x
LEGN ██% $7.07B x x
ALKS ██% $6.85B x 3.8x
RYTM ██% $6.77B x 65.7x
BLTE ██% $6.58B x 8.5x
BLRX ██% $6.58B x x
AMRX ██% $6.31B x x
LQDA ██% $6.13B x 31.4x
LGND ██% $6.01B 30.5x 6.2x
MIRM ██% $5.82B x x
TVTX ██% $5.71B x 233.0x
COGT ██% $5.61B x 10.5x
AMRN ██% $5.54B x 12.5x
PTCT ██% $5.23B x x
ERAS ██% $4.98B x 13.8x
DNTH ██% $4.95B x 4.2x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Veradermics, Inc Stock Forecast

How accurate are Veradermics, Inc stock predictions?

A per-ticker accuracy statistic for MANE is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Veradermics, Inc stock price forecasts?

Our analysis considers Veradermics, Inc's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Veradermics, Inc a good investment in 2026?

Based on our AI analysis, Veradermics, Inc shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Veradermics, Inc forecasts updated?

Veradermics, Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Sept. 25, 2026.

Want a simpler view of Veradermics, Inc?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...